Fortrea (FTRE) and Its Peers Financial Analysis

Fortrea (NASDAQ:FTREGet Free Report) is one of 47 public companies in the “Medical laboratories” industry, but how does it compare to its rivals? We will compare Fortrea to similar businesses based on the strength of its analyst recommendations, earnings, valuation, institutional ownership, profitability, risk and dividends.

Insider and Institutional Ownership

47.5% of shares of all “Medical laboratories” companies are owned by institutional investors. 0.1% of Fortrea shares are owned by company insiders. Comparatively, 18.8% of shares of all “Medical laboratories” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings for Fortrea and its rivals, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fortrea 1 5 5 1 2.50
Fortrea Competitors 308 1208 2107 33 2.51

Fortrea presently has a consensus price target of $32.30, indicating a potential upside of 38.39%. As a group, “Medical laboratories” companies have a potential upside of 24.95%. Given Fortrea’s higher possible upside, research analysts clearly believe Fortrea is more favorable than its rivals.

Earnings and Valuation

This table compares Fortrea and its rivals gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Fortrea $3.11 billion -$3.40 million -16.79
Fortrea Competitors $973.24 million -$121.96 million 4.52

Fortrea has higher revenue and earnings than its rivals. Fortrea is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.


This table compares Fortrea and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Fortrea -4.11% 4.76% 1.87%
Fortrea Competitors -3,337.10% -1,358.45% -41.71%


Fortrea beats its rivals on 7 of the 12 factors compared.

About Fortrea

(Get Free Report)

Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services, as well as consulting services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.

Receive News & Ratings for Fortrea Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortrea and related companies with's FREE daily email newsletter.